{
    "id": 3351,
    "fullName": "KIT D816G",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIT D816G lies within the protein kinase domain of the Kit protein (UniProt.org). D816G results in constitutive phosphorylation of Kit, is transforming in culture, and confers resistance to crizotinib (PMID: 27068398).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 12244,
                    "pubMedId": 27068398,
                    "title": "An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27068398"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "D816G",
    "createDate": "02/25/2015",
    "updateDate": "09/17/2018",
    "referenceTranscriptCoordinates": {
        "id": 136070,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54733155A>G",
        "cDna": "c.2447A>G",
        "protein": "p.D816G",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6911,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 24005,
                "profileName": "KIT W557_K558del KIT D816G"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6901,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 24005,
                "profileName": "KIT W557_K558del KIT D816G"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6906,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 24005,
                "profileName": "KIT W557_K558del KIT D816G"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6896,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",
            "molecularProfile": {
                "id": 24005,
                "profileName": "KIT W557_K558del KIT D816G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14560,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion developed resistance to treatment with Xalkori (crizotinib) and was subsequently found to have acquired KIT D816G (PMID: 29636358).",
            "molecularProfile": {
                "id": 30249,
                "profileName": "ROS1 fusion KIT D816G"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3161,
            "profileName": "KIT D816G",
            "profileTreatmentApproaches": [
                {
                    "id": 6126,
                    "name": "Avapritinib",
                    "profileName": "KIT D816G"
                },
                {
                    "id": 1237,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT D816G"
                }
            ]
        },
        {
            "id": 24005,
            "profileName": "KIT W557_K558del KIT D816G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30249,
            "profileName": "ROS1 fusion KIT D816G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136072,
            "transcript": "XM_005265741",
            "gDna": "chr4:g.54733155A>G",
            "cDna": "c.2447A>G",
            "protein": "p.D816G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136071,
            "transcript": "NM_001093772",
            "gDna": "chr4:g.54733167A>G",
            "cDna": "c.2447A>G",
            "protein": "p.D816G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136073,
            "transcript": "XM_017008179",
            "gDna": "chr4:g.54733167A>G",
            "cDna": "c.2447A>G",
            "protein": "p.D816G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136070,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54733155A>G",
            "cDna": "c.2447A>G",
            "protein": "p.D816G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}